Voyageur Pharmaceuticals Ltd. (TSX-V: VM) (OTC Pink: VYYRF) provided a corporate update and strategic roadmap on March 16, 2026, highlighting advancements in its barium and iodine contrast media projects. The company aims to address critical supply chain vulnerabilities in the diagnostic imaging sector, where demand is projected to grow from US$6.77 billion in 2024 to US$13.86 billion by 2033. With barite classified as a critical mineral by the U.S. Geological Survey, Voyageur is pursuing a vertically integrated supply chain for both barium and iodine active pharmaceutical ingredients, covering the entire value chain from mineral discovery to finished product manufacturing.
Voyageur is focused on completing two bankable feasibility studies (BFS): the Voyageur Radiology Iodine & Barium Drug Manufacturing Project and the Bayer Iodine Project. The Frances Creek barium contrast project, now in the BFS phase, hosts an indicated and inferred mineral resource of 132,000 tonnes of pharmaceutical-grade barium sulfate, with an average grade of 98.8% BaSO4, exceeding pharmaceutical grade standards. Product development initiatives for five Health Canada-approved barium products have been completed with Alberta Veterinary Laboratories, and initial contrast product sales of approximately C$32,000 have been generated, providing commercial validation. The company expects to deliver the FC barium BFS in the second half of 2026.
Regulatory pathways for barium and iodine contrast media are expected to follow an 18- to 24-month FDA review process, potentially enabling U.S. barium market entry as soon as mid-2027. Voyageur has completed first drafts of all barium FDA submission documents and formally commenced the approval process in February 2026 via the 505(b)(2) regulatory pathway. The FDA is expected to provide pending requirements in Q1 2026, with the review process anticipated to take approximately one year. Voyageur also plans to advance a generic iodine FDA license in the second half of 2026.
The Bayer Iodine Project, backed by a US$2.35 million funding arrangement, focuses on completing a BFS for iodine feedstock production. Subject to successful BFS, Bayer may provide capital financing for the project under an offtake-linked production financing arrangement, with Voyageur operating and managing the project. This collaboration represents an early step in Voyageur's mission to become the first domestic producer of iodine contrast in the United States, helping secure critical supply chains for North America's healthcare industry. All intellectual property developed in connection with the project will remain exclusively owned by Voyageur.
Voyageur is engaging with a global engineering company to complete the final BFS for both projects. Upon completion, the company will have finalized economics and plant design to vertically produce iodine and barium contrast media drugs, becoming the only vertically integrated radiology drug company in the marketplace. Voyageur is actively reviewing financial options to fund future capital expenditures, targeting construction to commence in 2027. The company's strategy aims to provide affordable and secure supplies for healthcare authorities worldwide, reinforcing its value proposition: From Earth to Bottle.
Voyageur is building a strong network of clients in Canada while developing international sales through clinics and distribution opportunities in Latin America, Middle East, North Africa, and Asia-Pacific regions. These efforts provide market intelligence on pricing and cost dynamics amid supply shortages, enabling Voyageur to meet urgent healthcare demands and expand global access to its barium contrast products. The company is working towards having multiple customers in place for the launch of FC barium contrast production after securing the CapEx to build the barium and iodine drug manufacturing facility.
